Sukumar Nagendran is President and Head of R&D of Taysha Gene Therapies, Inc.. Currently has a direct ownership of 897,843 shares of TSHA, which is worth approximately $1.66 Million. The most recent transaction as insider was on Jan 02, 2024, when has been sold 863,617 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 898K
0% 3M change
2523.28% 12M change
Total Value Held $1.66 Million

Sukumar Nagendran Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 02 2024
BUY
Grant, award, or other acquisition
-
863,617 Added 49.03%
897,843 Common Stock
May 16 2023
BUY
Open market or private purchase
$3,400 $0.68 p/Share
5,000 Added 12.75%
34,226 Common Stock
Feb 02 2022
BUY
Open market or private purchase
$80,100 $8.01 p/Share
10,000 Added 25.49%
29,226 Common Stock
Sep 28 2020
BUY
Conversion of derivative security
-
19,226 Added 50.0%
19,226 Common Stock

Also insider at

SLDB
Solid Biosciences Inc. Healthcare
SN

Sukumar Nagendran

President and Head of R&D
Dallas, TX

Track Institutional and Insider Activities on TSHA

Follow Taysha Gene Therapies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TSHA shares.

Notify only if

Insider Trading

Get notified when an Taysha Gene Therapies, Inc. insider buys or sells TSHA shares.

Notify only if

News

Receive news related to Taysha Gene Therapies, Inc.

Track Activities on TSHA